Failure of modified directly observed therapy combined with therapeutic drug monitoring to enhance antiretroviral adherence in a patient with major depression

AIDS Patient Care and STDs

Volumn 20, Issue 4, 2006, Pages 233-237

  Goicoechea, Miguel ^a,d   Best, Brookie ^a,b   Seefried, Edward ^a   Wagner, Glenn ^c   Capparelli, Edmund ^a   Haubrich, Richard ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c RAND CORPORATION   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TENOFOVIR; ZIDOVUDINE;

ADULT; ARTICLE; CASE REPORT; CHRONIC DRUG ADMINISTRATION; DIRECTLY OBSERVED THERAPY; DISEASE SEVERITY; DRUG MONITORING; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR DEPRESSION; PATIENT COMPLIANCE; PSYCHOSOCIAL CARE; SHORT COURSE THERAPY; SYMPTOMATOLOGY; TREATMENT OUTCOME;

ANTI-HIV AGENTS; DEPRESSIVE DISORDER, MAJOR; DIRECTLY OBSERVED THERAPY; FEMALE; HIV INFECTIONS; HUMANS; MIDDLE AGED; PATIENT COMPLIANCE;

EID: 33646082000     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2006.20.233     Document Type: Article

References (17)

1. Haubrich RH, Little SJ, Currier JS, et al. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group. AIDS 1999;13:1099-1107.
2. Ammassari A, Antinori A, Aloisi MS, et al. Depressive symptoms, neurocognitive impairment, and adherence to highly active antiretroviral therapy among HIV-infected persons. Psychosomatics 2004;45:394-402.
3. Tucker JS, Orlando M, Burnam MA, et al. Psychosocial mediators of antiretroviral nonadherence in HIV-positive adults with substance use and mental health problems. Health Psychol 2004;23:363-370.
4. d'Arminio Monforte A, Lepri AC, Rezza G, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naive Patients. AIDS 2000;14:499-507.
5. Behforouz HL, Farmer PE and Mukherjee JS. From directly observed therapy to accompagnateurs: Enhancing AIDS treatment outcomes in Haiti and in Boston. Clin Infect Dis 2004;38(Suppl 5):S429-436.
6. Stenzel MS, McKenzie M, Mitty JA, et al. Enhancing adherence to HAART: A pilot program of modified directly observed therapy. AIDS Read 2001;11:317-328.
7. Aarnoutse RE, Schapiro JM, Boucher CA, et al. Therapeutic drug monitoring: An aid to optimising response to antiretroviral drugs? Drugs 2003;63:741-753.
8. Lucas GM, Flexner CW, Moore RD. Directly administered antiretroviral therapy in the treatment of HIV infection: Benefit or burden? AIDS Patient Care STDs 2002;16:527-535.
9. Wagner G, Kanouse D, Miller L, et al. Cognitive-behavioral intervention to enhance adherence to ART: A randomized clinical trial (CCTG-578) [Abstract] In: 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA: 2005.
10. Haubrich RBB, Witt M, Goicoechea M, et al. Determinants of the need for therapeutic drug monitoring (TDM): Rates and predictors from CCTG 578 [Abstract 640]. In: 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA: 2005.
11. Murphy RL, Brun S, Hicks C, et al. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. AIDS 2001;15:F1-9.
12. Eron JJ, Feinberg J, Kessler HA, et al. Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: A 48-week randomized clinical trial. J Infect Dis 2004;189:265-272.
13. Hsu A, Isaacson J, Brun S, et al. Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2003;47:350-359.
14. Bing EG, Burnam MA, Longshore D, et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry 2001;58:721-728.
15. Moore RD, Keruly JC, Gebo KA, et al. An improvement in virologic response to highly active antiretroviral therapy in clinical practice from 1996 through 2002. J Acquir Immune Defic Syndr 2005;39:195-198.
16. Yasuda JM, Miller C, Currier JS, et al. The correlation between plasma concentrations of protease inhibitors, medication adherence and virological outcome in HIV-infected patients. Antivir Ther 2004;9:753-761.
17. Miller LG and Chang ES. Human immunodeficiency virus infection unresponsive to highly active antiretroviral therapy: Denial of poor medication adherence or recalcitrant infection? AIDS Patient Care STDs 2002;16:355-359.